Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
GlobeNewswire
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients..